Sergey Suchkov

Abstract

A new systems approach to subclinical and/or diseased states and wellness resulted in a new trend in the healthcare services, namely, personalized and precision medicine (PPM). To achieve the implementation of PPM concept, it is necessary to create a fundamentally new strategy based upon the biomarkers and targets to have a unique impact for the implementa-tion of PPM model into the clinical practice and pharma & medicinal chemistry bioindustry. In this sense, the translation of discoveries into therapies has not kept pace with medical need. It would be extremely useful to integrate data harvesting from different databanks for appli-cations to provide more tailored measures for the patients and persons-at-risk resulting in improved outcomes.

Translational researchers, biodesigners, bio- and chemical engineers, and manufacturers are beginning to realize the promise of PP. Biodesign, bio- and chemical engineering, and nanobi-otechnologies are being integrated into diagnostic and therapeutic tools to manage an array of PPM-guided conditions to customize therapeutic management. Partnering and forming strategic alliances between researchers, biodesigners, bio- and chemical engineers, clinicians, business, regulatory bodies and government can help ensure an optimal development pro-gram that leverages the Academia and industry experience and FDA’s new and evolving toolkit to speed our way to getting new tools into the innovative markets.

Healthcare is undergoing a transformation, and it is imperative to leverage new technologies to sup-port the advent of PPM. It is needed to discover, to develop and to create new (targeted and/or smart/intelligent) drugs being based on design-driven bio- and chemical engineering. In this context and as an example, abzymes are increasingly attractive in a bioindustrial setting as an environmentally friendly alternative to canonical chemical catalysts. To produce the ideal biocatalyst, abzymes often require optimization to increase their catalytic efficiencies and specificities under a particular range of reaction conditions. A number of abzyme engineering strategies are crucial to modify biocatalysts, improving their suitability for large-scale applica-tions in clinical practice and bioindustry.

Of great interest are innovative platforms for the diagnosis, prognosis, and precision care of patients and pre-illness persons-at-risk, and integrating state-of-the-art abzyme-related bio-engineering and computational tools to create novel biomarkers and therapeutic targets that will open new frontiers in the treatment of chronic diseases. Biocatalyst-related principles are pioneered for creating a new generation of supramolecular nanomaterials in order to develop personalized cancer treatment and vaccines. With the support of nanotechnology, new tar-geted therapeutic agents and biomaterials, or aid the development of assays for disease bi-omarkers and identification of potential biomarker-target-ligand (drug) tandems to be used for the targeting, PPM is making phenomenal steps in the future to come.

Applications of natural and design-driven biocatalysts as a product of engineering biology and biotech aimed for PPM-guided practice and bioindustry, are highly diverse and will change our world. Advances in healthcare, agritech and food industry include new drugs that reduce en-vironmental harm and foods that are more nutritious and easier to grow. They can improve our food security, helping tackle one of our great global challenges. The latter can also deliver a more sustainable chemical design and industry, drastically reducing the use of poisons for the manufacture of bioproducts. Scaling up from a laboratory reaction to an industrial process is the main challenge for chemical and bioengineers resulting in the optimization at many lev-els. Moreover, developing and optimizing chemical and biotechnological processes plays a key role in modern society. This is the reason for developing global scientific, clinical, social, and educational projects in the area of PPM and design-driven translational applications to elicit the content of the new trend. The latter would provide a unique platform for collaboration among thought leaders and stakeholders in government, academia, industry, foundations, with an interest in improving the system of healthcare delivery and drug discovery, develop-ment, and translation.